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Abstract
Background: Our understanding of pro-resolution factors in determining the outcome of inflammation has recently gained
ground, yet not many studies have investigated whether specific genes or patterns of genes, are modified by these
mediators. Here, we have focussed on the glucocorticoid modulated pro-resolution factor annexin A1 (AnxA1), studying if
its interaction with the ALX receptor would affect downstream genomic targets.
Methodology/Principal Findings: Using microarray technology in ALX transfected HEK293 cells, we discovered an over-
lapping, yet distinct gene activation profile for AnxA1 compared to its N-terminal mimetic peptide Ac2-26, which may be
suggestive of unique downstream inflammatory outcomes for each substance. When the up-regulated genes were
explored, consistently induced was the sphingosine phosphate phosphatase-2 gene (SGPP2), involved in regulation of the
sphingosine 1 phosphate chemotactic system. Up-regulation of this gene, as well as JAG1 (and down-regulation of JAM3),
was confirmed using real time PCR both with transfected HEK293 cells and human peripheral blood leukocytes.
Furthermore, lymph nodes taken from AnxA1
null mice displayed lower SGPP2 gene activity. Finally, connectivity map
analysis for AnxA1 and peptide Ac2-26 indicated striking similarities with known anti-inflammatory therapeutics,
glucocorticoids and aspirin-like compounds, as well as with histone deacetylase inhibitors.
Conclusion/Significance: We believe these new data raise the profile of AnxA1 from being solely a short-term anti-
inflammatory factor, to being a ‘trigger’ of the endogenous pro-resolution arsenal.
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Introduction
The concept of endogenous anti-inflammation has gained
ground recently with various mediators being identified: they are
actively involved in controlling and attenuating the potential
over-reaction of the body’s immune system, thereby affording a
degree of protection for the host, assuring a strict time-
dependence of the acute inflammatory response and promoting
rapid regain of homeostasis [1,2,3,4]. Among the group of pro-
resolving endogenous anti-inflammatory mediators, glucocorti-
coids represent one of the main pathways. Released by the
concerted action of hormones acting on the hypothalamus,
pituitary and adrenal glands, glucocorticoids augment the
cellular levels of a downstream anti-inflammatory mediator,
the 37-kDa protein Annexin 1 (AnxA1, formerly named
lipocortin-1). Blood-borne polymorphonuclear leukocyte (PMN)
represents the first line of defence in innate immunity, as they are
the first to rapidly extravasate to the site of inflammation. The
function of early/non-genomic effects of AnxA1 on the PMN, in
the context of the endogenous control against over-shooting of
inflammation, are well characterised and include inhibition of
PMN extravasation in models of acute [5] and chronic
inflammation [6] as well as in experimental systemic inflamma-
tion [7] have been described.
Many of the cellular effects of AnxA1 are mediated by a specific
G-protein-coupled 7-transmembrane receptor, termed ALX. This
receptor is shared by another effector of endogenous anti-
inflammation, the short-lived lipid lipoxin A4 [8], hence the
acronym ALX for lipoxin A4 receptor. However, ALX is also
structurally related to the human formyl-peptide receptor or FPR,
hence sometimes it is referred to as FPR-like-1 or FPR2 [9]; [10].
Here, we will use the ALX classification, as this terminology is
more relevant to the anti-inflammatory functions of this receptor.
Human FPR is the classic receptor for the chemoattractant
formyl-Met-Leu-Phe, whereas ALX displays ,70% similarity at
the nucleotide level, and binds several synthetic and natural
ligands, examples of the latter ones being serum amyloid A, lipoxin
A4 and AnxA1 [8,11].
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large replicated by short peptides derived from the N-terminal
sequence of the 346-aa long protein. For example, peptide Ac2-26
retains most of the anti-migratory actions of AnxA1 [12,13]
however, using artificial transfected cell systems, peptide Ac2-26
has been shown to activate human FPR [14,15] as well as the third
receptor of this family, termed FPR-like 2 [14]. We have recently
transfected human FPR and ALX (the only two receptors of the
group expressed by human PMN) in HEK293 cells finding that
while AnxA1 displays selectivity for binding to ALX, the shorter
and more flexible peptide Ac2-26, binds to both FPR and ALX
with approximately equal affinity [16]. Analysis of the rapid post-
receptor events indicated selective activation of the extracellular-
regulated kinase 1 and 2 pathway, with no activation of other
mitogen-activated protein kinase [16]. Finally, AnxA1 activation
of ALX on the human PMN inhibited interaction with HUVEC
monolayers as assessed with the flow chamber system.
The present study was undertaken to identify other effects
downstream the AnxA1/ALX pathway, reasoning that delayed
gene alteration might have implications in the control exerted by
AnxA1 in complex and longer lasting inflammatory scenarios. In
addition, a comparison between the genes altered by AnxA1 and
its short N-terminal derived peptide Ac2-26 [17] was also made,
supposing that a more rigid conformation, as in the full protein
binding to ALX vs. a more flexible structure, as in the case of 24-aa
long peptide Ac2-26, might incite distinct modes of activation of
the receptor.
Materials and Methods
AnxA1 and Ac2-26 synthesis
Human AnxA1 cDNA was cloned into the expression vector
pGEX-4T-327 and the protein expressed and purified (Scientific
Proteins, Witterswil, Switzerland). AnxA1 was expressed as a
fusion protein with major basic protein linked to the N-terminal
and subsequently cleaved with TEV protease. Sodium dodecyl
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and west-
ern blot analysis showed that the recombinant AnxA1 was more
than 98% pure, with an endotoxin contamination less than 40 U/
mg as measured by the Limulus amebocyte chromogenic assay
(Sigma, Poole UK). Peptide Ac2-26 (acetyl-AMVSEFLKQAWIE-
NEEQEYVVQTVK; corresponding to residues 2-26 of human
AnxA1) was synthesised by the Advance Biotechnology Centre
(Imperial College School of Medicine, London, UK) using solid-
phase stepwise synthesis. Purity was more than 90% as assessed by
high-performance liquid chromatography (HPLC) and capillary
electrophoresis (data supplied by the manufacturer).
Receptor cloning and cell culture of stably transfected
HEK293 cells
HEK293 cells were obtained form the European Collection of
Cell Cultures (ECACC 85120602). ALX receptor was cloned in
HEK293 cells and cultured as recently described [16]. Briefly,
cloning the cDNA encoding the open reading frame of the
receptor was obtained by PCR amplification of U937 cell cDNA
library, using the forward primer, 59-GCG CAA GCT TAT GGA
AAC CAA CTT CTC CAC TCC TC, and reverse-purified and
ligated in to pRc/CMV expression vector (Invitrogen, Paisley,
UK), by sticky end ligation. The ALX construct was used to stably
transfect HEK-293 cells using Fugene 6
TM transfection reagent
(Roche, Lewes, UK) according to manufacturer’s instructions. In
brief, 2 mg of plasmid DNA was used to transfect HEK-293 cells
(2610
5 cells/well in 6 well plates) cultured in supplemented
Eagle’s minimum essential medium (EMEM). Neomycin (400 mg/
ml; Invitrogen) was added to the medium to maintain selection.
Cell Staining and Flow Cytometry
To detect membrane ALX, stably-transfected HEK293 cells
were suspended in PBC buffer (0.15% BSA, 1 mM CaCl2 in PBS)
and incubated with either primary monoclonal antibody for
human ALX receptor (final concentration of 5 mg/ml; a kind gift
from Dr Duncan Henderson (AstraZeneca, UK) or PBC alone. All
samples were also incubated with human IgG at 320-mg/well
(Sigma, UK) for 1 h at 4uC. Following washes with PBC, cells were
incubated with rabbit anti-mouse FITC (STAR 9B, Serotec, UK)
at 1:40 dilution, for 45 minutes. Samples were washed and
analysed by flow cytometry using a FAC-SCalibur (Becton
Dickinson) cytometer. Data was acquired and analyzed using the
CellQuestH. Mean fluorescence intensity was evaluated.
Microarray Hybridization, Data Processing and Functional
Analysis
The microarray analysis was performed on GeneChipH Human
Genome U133 Plus 2.0 Arrays (Affymetrix, Inc. Santa Clara,CA),
which include 54,675 probe sets that represent over 38,500 well-
characterized human genes.
We used two replicates for each group: CMV (control group,
HEK293 cells), ALX (HEK293 transfected with ALX receptor),
Ac226 (HEK293 cells transfected with ALX receptor and treated
with 10 mM Ac2-26 peptide) and AnxA1 (HEK293 cells
transfected with ALX receptor and treated with 0.5 mM AnxA1
peptide).
All sample labelling, hybridization, staining and scanning
procedures were carried out using Affymetrix standard protocols
(www.affymetrix.com). Briefly, total RNA was purified 4 hours
after treatment with the peptides, using Trizol (Invitrogen)
method, according to manufacturer’s instructions. To assess the
quality of the RNA used for microarray experiments all samples
were analysed using an Agilent Bioanalyser 2100. The RNA
profiles for each sample were within the range recommended by
the manufacturer. Then, cDNA was synthetized from total RNA
and an in vitro transcription reaction was performed to obtain
biotin-labelled cRNA, which was then fragmented and hybridized
to the chips. After incubation, washing and staining steps, intensity
signal for each probe set was measured.
Normalization was carried out using Bioconductor software
(affyPLM package, RMA method). Normalized intensity values
were used to obtain the fold change (FC) for each of the three
groups studied (ALX alone, Ac2-26 and AnxA1) calculating the
log2 of the ratio (average of the two replicates/average of the two
control replicates). We also performed an exhaustive quality
control study using Bioconductor (simpleAffy package), including
visual inspection of the microarrays, % present genes, average
background, scale factor, GAPDH 39/59 ratio and spike in controls.
All of them showed normal values.
Data analysis and filtering were made with Spotfire DecisionSite
v9.0. Genes with a FC more than a 50% compared to controls
were considered differentially expressed. The functional analysis of
differentially expressed genes (3120, 103 and 118 probes for ALX,
Ac226 and AnxA1 groups respectively) was made using Panther
Classification System v6.1 (Applied Biosystems).
Finally, according to MIAME recommendations and in order to
ensure that all information is given in detail so results can be easily
understood, reproduced and compared, all microarray data are
publicly available in the Gene Expression Ommibus (GEO)
database (GEO ID: GSE14807).
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RNA was extracted using Trizol solution according to the
manufacturers instructions. ,25 mg total RNA were treated with
DNAse 1 (Ambion, UK) for 1 hr at 37uC. Total RNA for all
experiments was normalised at 5 mg/reaction. cDNA was
produced using SuperScript
TM III (Invitrogen Ltd, Paisley,UK).
PCR was performed using the following specific primers: hALX
receptor: 59-TAT TGC CAC CAA GAT CCA CA (forward, F),
59-GA GGC AGC TGT TGA AGA AGG (reverse, R); hFPR: 59-
CAA CCC CAT GCT TTA CGT CT (F), 59-T ATC CCT GAC
CCC ATC CTC (R); hGAPDH: 59-CAA ATT CCA TGG CAC
CGT CA (F), 59-GGA CTG GGT GTC GCT GTT GA (R).
PCR amplification conditions were as follows, 94uC for 5 mins
then 35 cycles of 94uC for 30 seconds, 59uC annealing for 30
seconds, 72uC extension for 30 seconds then 7 minutes at 72uC.
Products were run immediately on a 1% agarose gel and
photographed under ultra-violet light. Human primary neutrophil
cDNA was used as a positive control for ALX receptor and FPR1
mRNA expression.
Real-time-PCR using SYBR Green I Dye chemistry and
data analysis
Samples were normalised to 40 ng of cDNA per well and
loaded in triplicate for each gene. QuantiTect primer assays
(Qiagen Ltd, UK) were used: hGAPDH (QT01192646); hRPL32
(QT00046088); hSGPP2 (QT00041832), hJAG1 (QT00031948),
mJAM3 (QT00024997), mGAPDH (QT 0199388); mRPL32
(QT0131992) mSGPP2 (QT 01044204). Sample cDNA was
obtained using SensIMix(dT) 2x mastermix and SYBRHGreen 1
(Quantace Ltd, UK) using an ABI PRISMH 7900HT fast real time
PCR system (ABI, Ca). PCR ramping protocols were standardised
for all QuantiTect primer assay sets at 50uC for 2 min, 94uC for 5
min, followed by 40 cycles of 30 s at 94uC, 45 s at 55uC and 45 s
at 72uC. GAPDH and RPL32 were used as endogenous controls.
Data analysis was made using Relative Expression Software Tool
(REST).
Animals
Animal work was performed by authorised scientists (holding a
personal licence) according to UK Home Office regulations
(Guidance on the Operation of Animals, Scientific Procedures, Act
1986) and complying with the directives of the European Union
(project licence 70/5882 scrutinised by Queen Mary Ethics
Committee first and then approved by the Home Office, on April
2004)". Male wild type (WT) Balb-c mice (20–25 g) were
purchased from B&K (Hull, UK). AnxA1 null Balb-c mice (20–
25) were backcrossed from the original mixed C57Bl6/129SV [18]
for 10 generations. Five animals were housed per cage with 12 h
light-dark cycle and controlled temperature. Animals were
maintained on a standard chow pellet diet with tap water ad
libitum.
Isolation of primary human leukocytes
Experiments using healthy volunteers were approved by the
local research ethics committee (05/Q0603/34 Barts and The
London Research Ethics Commitee). Informed consent was
provided according to the Declaration of Helsinki. Consent was
verbal as per protocol approved, since dealing with healthy control
blood. Each time samples were taken from healthy volunteers, a
record of the amount of blood and date was written in a dedicated
log book. Only blood from healthy volunteers was used for this
study (no patient samples), which was used for leukocyte
purification. Volunteers consented to allow the use of their white
blood cells (via methods described below) for in vitro experiments.
Blood was collected into 3.2% sodium citrate and diluted 1:1 in
RPMI-1640 (Sigma-Aldrich) before separation through a Histo-
paque 11191/10771 gradient. After PBMC/PMN isolation and
washing, contaminating erythrocytes were removed by hypotonic
lysis. PBMC/PMN’s were resuspended at a concentration of
50610
6/mL in PBS supplemented with Ca
2+ and Mg
2+. PBMC/
PMN cells were incubated at 37uC in a shaking water-bath for 4
hrs with and without human recombinant AnxA1 (500 nM).
Following the incubation samples were centrifuged at 4000 g for 5
minutes and supernatant discarded. Samples were frozen at
280uC in Trizol until RNA purification.
Results and Discussion
Transfection of ALX receptor in HEK293 Cells
HEK293 cells were chosen as a host cell for transfection
experiments, as they lack endogenous FPR family receptors,
including ALX receptor. The extent of ALX expression in stably
transfected HEK293 cells was confirmed using specific primer
sequences designed against the protein coding region of the
human ALX receptor (Figure 1B). Control/empty vector stably
transfected HEK293 cells demonstrate a lack of expression of
either FPR or ALX receptor genes. Human neutrophil cDNA was
used as a positive control. Expression of ALX receptor cell surface
protein was demonstrated in unstimulated ALX stably transfected
HEK293 cells compared to empty vector controls (CMV) using
flow cytometry analysis (Figure 1C). There was a significant
increase in positive fluorescent signal, in the ALX receptor
transfected cells compared to CMV cells. No significant increase in
fluorescent signal was observed when using an FPR specific
antibody on either cell type (data not shown) demonstrating a lack
of FPR receptor protein in these cells. Of equal importance, CMV
or ALX-transfected cell incubation with 10 mM peptide Ac2-26 (4
h) did not yield any expression/release of endogenous AnxA1 (as
assessed by Western blotting in cell-free supernatants), Lipoxin A4
or SAA (assessed by ELISA) (data not shown).
These results suggest that the ALX transfected HEK293 cells
have both i) detectable cell surface expression in the ALX protein
and ii) that this expression is specific to the cloning procedure, as
CMV empty vector transfected cells show no immunoreactivity for
the anti-ALX antibody. There was also no detectable release of
AnxA1 protein from either transfected cell line (as measured by
ELISA, data not shown), suggesting that there was no interference
by endogenous AnxA1 protein in the transfected HEK293 cells in
the subsequent microarray experiments.
Identification of differentially expressed genes by AnxA1
and peptide Ac2-26
In order to obtain a global picture of gene expression changes
associated with the activation of ALX receptor by the specific
agonists AnxA1 and peptide Ac2-26, a whole-genome microarray
study was carried out using GeneChipH Human Genome U133
Plus 2.0 (Affymetrix, Santa Clara, CA). HEK293 cells transfected
with ALX receptor were treated with 0.5 mM AnxA1 or with
10 mM Ac2-26 for 4 hours; these concentrations were validated to
produce rapid signalling responses (e.g. phospho-ERK) via ALX
activation [16]. Cells containing the ALX receptor were used as
controls. Also, a fourth group was included, consisting of HEK293
cells transfected with empty vector, which served as control to
study the changes produced by the transfection of the receptor in
these cells.
After an exhaustive quality control and normalization steps (see
Material & Methods), Spotfire Decision Site software was used to
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AnxA1 and Ac2-26), probes showing a fold change $50%
compared to controls, were selected as differentially expressed.
As shown in Figure 2, the transfection of the ALX receptor into
HEK293 cells produced strong changes on gene expression: 3120
probes, of which 2893 were down-regulated and only 227 were
up-regulated. This strong effect on gene expression could be due to
the artificially over-expression of the receptor that is observed in
these cells after the transfection. On the other hand, 118 and 103
probes were differentially expressed after treatment with AnxA1
and Ac2-26 peptides respectively, compared to control group
(ALX). These genes are summarized in Supplementary Tables S1
and S2.
A succinct list of the interesting genes affected by both AnxA1
and Ac2-26 would include SGPP2 (sphingosine-1-phosphate
phosphatase), an enzyme involved in the degradation of
sphingosine-1-phosphate (S1P), a lipid mediator involved in
several physiological processes including cell growth and survival,
and leukocyte migration [19,20]. S1P has also been shown to play
a role in pathological conditions including vascular permeability,
cancer and inflammation and recent reports show that SGPP2,
one of the enzymes involved in its regulation is induced during the
inflammatory process [21] as well as in experimental osteoarthritis
[22].
Another gene of interest was JAM3 (junctional adhesion
molecule 3, also known as JAMC), which was down-regulated
Figure 1. Transfection of ALX receptor into HEK293 cells. A) Generation of the HEK293 clones. pRc/CMV expression vector used to transfect
ALX receptor into HEK293 cells to produce stable cell lines. Details of the full length protein sequence for the ALX receptor are also shown. B)
Representative expression of FPR receptors by PCR visualised on a 1% agarose gel: CMV, empty vector transfected cells; ALX, annexin A1 receptor
transfected cells; (+) human neutrophil cDNA positive control; (2) water replaced cDNA negative control. In all experiments results are representative
of three separate experiments with similar results. C) Specific ALX receptor immunoreactive protein cell surface expression was determined using
flow cytometry and compared to CMV stably transfected HEK293 cells.
doi:10.1371/journal.pone.0012771.g001
Figure 2. Filtering process and identification of differentially expressed probes in ALX, Ac226 and AnxA1 groups. Internal controls
contained in the array were discarded. Then, probes showing a fold change (FC) less than 50% in expression for each group (ALX vs. CMV, Ac226 vs.
ALX, AnxA1 vs. ALX) were selected as differentially expressed probes.
doi:10.1371/journal.pone.0012771.g002
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in transendothelial migration of leukocytes [23]. Recent data
suggest potential roles for this protein in the pathogenesis of
rheumatoid arthritis, being highly expressed in rheumatoid
synovium. Moreover, targeting JAM3 significantly reduced the
severity of experimental arthritic disease [24,25]. We would
propose that down-regulation of this gene by AnxA1 may
contribute to its inhibitory properties in models of chronic
inflammation. As an example, work of Morand and colleagues
have highlighted the importance of this mediator in modulating
inflammatory arthritis [6,26]. Our new data indicate that, in
inflammatory settings, expression of JAM-3 may be modulated
upon AnxA1 administration (pharmacological studies) or AnxA1
deficiency (patho-physiological investigations).
Next, we used a distinct approach where we compared the three
groups in order to find similarities and/or differences in gene
expression changes that could be related to the mechanism of
action of these peptides. The Venn diagram in Figure 3 reports the
7 common probes that are affected in the three groups.
Surprisingly, only 19 probes were differentially expressed between
AnxA1- and Ac2-26-treated cells. Some of these genes include the
Sp1 transcription factor, SGPP2, EVI5 gene, involved in cell cycle
regulation, the transferrin receptor (TFRC) or C19ORF6, also
called membralin, which has been associated with ovarian
carcinoma (Figure 3).
Functional analysis of ALX, AnxA1 and Ac2-26
differentially expressed genes
To further analyze the biological meaning of gene alteration
detected in our experiments, we performed a functional study
using Panther Classification System which classify genes according
to biological process, molecular function and pathways. Figure 4
illustrates the most interesting categories involved in ALX
transfected cells (left) and AnxA1 and Ac2-26 treated cells (right).
Nucleic acid metabolism and protein metabolism and modification
appear as the most affected processes in the ALX group. Other
interesting categories include cell structure and motility, transcrip-
tion factors as well as pathways related to immunity such as
inflammation mediated by chemokine and cytokine and integrin
signaling pathways (Figure 4).
As expected, ALX receptor (or FPR2) was up-regulated,
showing a fold change of 1.55. Among genes related to immunity,
we detected a significant down-regulation in IFNGR1 (interferon
gamma receptor), IL6ST (interleukin 6 signal transducer) and
several suppressors of cytokine signalling molecules (SOCS2,
SOCS4, SOCS5 and SOCS6). In addition, several surface
molecules, including CD109, CD164 and CD24, were down-
regulated as well as chemokine (CXC motif) receptor 4, a
chemotactic receptor with a critical role in tumor progression, and
TIA1 (TIA cytotoxic granule-associated RNA binding protein), a
protein with nucleolytic activity against cytotoxic lymphocyte
target cells.
Regarding the treatment with AnxA1 or Ac2-26, they seem to
affect predominantly the same functions, although some differ-
ences could also be observed. For example, AnxA1 altered a
higher number of genes related to cell proliferation and
differentiation, transcription factors and transferases, while peptide
Ac2-26 affected more genes involved in immunity and defense,
phospholipid metabolism and kinases, to name just a few. The
most interesting genes emerged in our study are those related to
Figure 3. Common differentially expressed probes among ALX, AxnA1 and Ac2-26 groups. A) Venn diagram comparing the differentially
expressed probes identified in each group (ALX, Ac226 and AnxA1). B) Expression of the 7 probes differentially expressed in all groups and the 19
probes differentially altered by the two peptides (Ac226 and AnxA1), obtained from the Venn diagram. Up-regulated probes are displayed in red and
down-regulated in green.
doi:10.1371/journal.pone.0012771.g003
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transcription factor involved in the immune response, which is
down-regulated by both peptides.
Another striking finding was the up-regulation of JAG1
consequent to AnxA1. Microarray data were confirmed by real
time PCR (Figure 5A). The protein encoded by this gene is the
ligand for the receptor Notch 1, which plays an important role
during T-cell development. This is in line with recent observations
of our group [27] where AnxA1 modulates not only the innate
system, but also T-cell functions. Furthermore, it has been
reported that administration of anti-JAG1 antibody exacerbates
experimental autoimmune encephalomyelitis [28], suggesting a
potential role of this gene as a therapeutic target for inflammatory
conditions. We believe these novel findings will feed into future
studies aiming at clarify the complex and positive actions of
AnxA1 on T cells and other immune responses [13,29].
Real Time-PCR validation of selected genes
In order to confirm the gene expression changes obtained in the
microarray experiment, we performed real time-PCRs using
SYBR Green I Dye chemistry. We focused here on three genes:
SGPP2, as it controls the trafficking of lymphocytes in the thymus
and lymphoid organs [19], JAG1, which is related to T cell
function and could be related to the role of AnxA1 in the adaptive
immune system [13,29], and JAM3, as previously mentioned.
Quantitative PCR experiments confirmed that the altered gene
expression of these genes by AnxA1 was genuine (Figure 5A).
Although HEK293 cells lack receptors for AnxA1, these
experiments were carried out using empty vector-transfected cells
(CMV) treated with AnxA1 as controls, showing therefore that the
effect of the protein is genuinely due to interaction with ALX, and
not the result of non-specific interaction with other receptors
present on the plasma membrane of HEK293 cells.
Figure 4. Functional analysis of differentially expressed genes. Representative categories of biological process, molecular functions and
pathways are shown. Functional analysis of the 3120 differentially expressed probes in ALX group (left) and analysis of the 103 and 118 altered probes
in Ac226 and AnxA1 groups, respectively (right). Panther Classification System was used for this analysis.
doi:10.1371/journal.pone.0012771.g004
Figure 5. Real time-PCR validation. A) Gene expression of SGPP2, JAG1 and JAM3 in ALX-HEK293 transfected cells compared to empty vector-
transfected cells (CMV group). B) Gene expression of SGPP2 in human peripheral mononuclear cells (PBMC) and polymorphonuclear cells (PMN),
under control conditions (Ctrl) or after 4 h incubation with 0.5 mM AnxA1 (AnxA1). C) mSGPP2 gene expression in lymph nodes and thymuses of wild
type (WT) and AnxA1
null mice. (*p,0.05, t-Test compared to controls (A,B) or wild type (C)).
doi:10.1371/journal.pone.0012771.g005
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Thus we could confirm its over-expression in PBMCs and PMNs
isolated from healthy human donors after incubation with 0.5 mM
AnxA1 for 4 hours. Figure 5B shows a significant (p,0.01, n=6)
increase in SGPP2 expression in both type of cells, suggesting that
AnxA1 can up-regulate SGPP2 expression not only in an artificial
system (e.g. transfected HEK293 cells which over-express ALX), but
alsoinprimaryhumanleukocytesthatnaturallyexpressthereceptor.
SGPP2 expression in AnxA1
null mice
Although the function of AnxA1 has been mainly described in
terms of the innate immune system, recent data suggest a role for
AnxA1 in the adaptive immune system and the determination of
Th1/Th2 phenotypes of T cells [13,27]. According to this recent line
of research, and supported by our novel finding of the up-regulation of
SGPP2 enzyme by AnxA1, we decided to investigate the relationship
between AnxA1, T cells and SGPP2. Thus, we compared the
expression levels of SGPP2 in peripheral lymph node and thymus
tissues from AnxA1
null a n dw i l dt y p e( W T )a n i m a l sb yr e a lt i m e - P C R .
Figure 5C shows a significant decrease in SGPP2 expression in
both tissues, when they were harvested from AnxA1
null mice,
strongly suggesting a key regulatory function for AnxA1 on
constitutive SGPP2 gene expression. There is positive regulation
upon AnxA1 (or peptide Ac2-26) addition, conveyed by ALX
activation, and there is also negative regulation in tonic absence of
this protein, as observed in AnxA1
null mice.
Relationship of AnxA1 and Ac2-26 to other compounds
using a gene-expression based screening approach
The Connectivity Map is a repository of the gene expression
profiles of cultured human cells exposed to small bioactive
molecules. It contains more than 7000 gene expression signatures
representing 1309 different compounds. This map represents a
tool for the large-scale discovery of connections among small
molecules, genes and diseases [30,31]. This tool was used to reveal
potential expected, and unexpected, connections between AnxA1
and Ac2-26 peptides and other chemical compounds, which could
provide new information about their mechanism(s) of action. This
approach has been recently applied with success to reveal the
HSP90 inhibitory activities shared by a natural antioxidant
molecule celastrol and the antimalarial agent gedunin [32].
Furthermore, Wei et al used the Connectivity Map to demonstrate
that rapamycin modulates glucocorticoid resistance [33]. There-
fore, we queried the Connectivity Map using the AnxA1 and Ac2-
26 expression signatures obtained in our microarray analysis. The
result is a ranking of all compounds included in the map, ordered
by their similarity with our data: molecules with an expression
profile similar to the expression profile of interest (e.g. AnxA1) will
be found at the top of the ranking (positive score), while drugs
displaying an opposite expression profile (negative score) will be
located at the bottom of the list.
Figure 6 summarises our analyses for AnxA1 and peptide Ac2-
26. It was re-assuring that the Connectivity Map found several
connections between our peptides and known anti-inflammatory
drugs. For example, peptide Ac2-26 displayed similarities in gene
expression patterns with glucocorticoids such as budesonide (score
of 1) and fluocinonide (score of 0.75), as well as with several
NSAIDs including diflunisal, ketorolac and zomepirac (scores of
0.95, 0.87 and 0.82, respectively). In a similar fashion, several anti-
inflammatory drugs showed positive connectivity score with
AnxA1 (see Figure 6). With respect to novel connections, it was
interesting to note a high positive score for peptide Ac2-26 and
antibacterial drugs as well as, perhaps more importantly for
AnxA1, with histone deacetylase inhibitors (HDACIs).
Figure 6. Connectivity Map results. Connectivity Map analysis of differentially expressed genes by 10 uM Ac2-26 peptide (103 genes) -left- and
0.5 uM AnxA1 (118 genes) -right-, in HEK293 cells transfected with the receptor ALX. Bar-views are constructed from more than 7,000 horizontal lines,
each representing an individual treatment instance, ordered by their corresponding connectivity scores (+1, top; -1, bottom). Drugs with positive
score are represented in green, while those with negative connectivity score are displayed in red. Only compounds with a positive score $0.75 are
reported. A selection of these compounds is summarized in the table (middle).
doi:10.1371/journal.pone.0012771.g006
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relation refers to the potential role of peptide Ac2-26 as anti-
bacterial, as occurs with many other peptides, including
melanocortin peptides [34,35]. In order to test this hypothesis,
we performed a minimum inhibitory concentration assay using
several microorganisms (E. coli, P. aeruginosa and MRSA), following
incubation with a concentration-range of peptide Ac2-26, but no
significant effect was observed (data not shown). However, a
different hypothesis might also emerge, inasmuch as antibacterial
compounds might produce anti-inflammatory effects similar to
those of peptide Ac2-26. Further studies will test this hypothesis,
though it is worth noting that in the case of some antibiotics, such
anti-inflammatory properties have already been shown (e.g. for
tetracyclines see [36]). We identified metacycline connected to
peptide Ac2-26 (score of 0.79; Figure 6). Furthermore, sulfasala-
zine is a sulfonamide that, in addition to its use as an antibiotic, is
commonly used for the treatment of rheumatoid arthritis and
inflammatory bowel disease patients. Our analysis highlighted two
sulfonamides, sulfamerazine (score of 0.82) and mafenide (score of
0.87), suggesting that it could be worthwhile pursuing this type of
compound as potential anti-inflammatory drugs.
The results obtained from AnxA1 were also very striking. We
observed a strong, and unexpected, connection between AnxA1
and HDACIs, with several hits for Trichostatin A (scores ranging
from 0.88 to 0.75). These compounds have already been
successfully used as anti-inflammatory drugs in several experi-
mental models, including rheumatoid arthritis [37], colitis [38]
and traumatic brain injury [39].
HDACIs have been extensively studied as anticancer drugs due
to their ability to induce apoptosis but the mechanism of action is
not completely clear. Two recent reports suggest that the
mechanism of action of HDACI-induced apoptosis might be
linked to up-regulation of the pro-apoptotic protein AnxA1 [40].
On the other hand, AnxA1 augments leukocyte apoptosis and
favours the removal of apoptotic cells by phagocytes (efferocytosis)
[41,42]. According to this and the novel connection between
AnxA1 and HDACIs found in our results, we can hypothesise that
- in line with anti-cancer activities [43] - the anti-inflammatory
mechanism of action of HDACIs (still a matter of debate) could
entail up-regulation of one of the effectors of endogenous anti-
inflammatory processes, the protein AnxA1.
The Connectivity Map analysis also demonstrated similar
profiles of gene expression for AnxA1 and two widely used
glucocorticoids, beclomethasone and triamcinolone. Therefore,
our genomic analysis validated long-dated experiments that have
demonstrated the intermediate role for AnxA1 in specific anti-
inflammatory activities of glucocorticoids (summarised in [44]).
In conclusion, this study reports the novel observation that
AnxA1 is a regulator of SGPP2 in an ALX-dependent fashion.
This gene was not only up-regulated by ALX-HEK293 cells but
also in primary cells, i.e. human PMN and PBMCs. Conversely,
lower SGPP2 expression levels were measured in tissues taken
from AnxA1
null mice. Altogether, these data indicated potentially
strong and novel links between the AnxA1 pathway and S1P
biology, paving the way for further functional investigations.
Another up-regulated gene, validated by real time PCR, was
JAG1, pointing to a regulatory role of AnxA1 on T cells by means
of sustained alteration of genes central to their development and
differentiation. The down-regulation of JAM3 is also interesting as
it is involved in leukocyte migration [23], a process in which
AnxA1 have already been implicated. For instance, AnxA1
null
mice display a higher degree of leukocyte trans-migration across
post-capillary venules in response to a variety of stimuli [45],
which could be consequent to higher JAM3 expression hence
function to sustain cell migration. Future studies will challenge this
hypothesis.
An interesting observation was the partial overlap between the
AnxA1 and peptide Ac2-26 signature. Peptide Ac2-26 can mimic
many of the anti-inflammatory properties of the parent protein,
but it is clear that there may be downstream events which are
specific for AnxA1. On the other, we have previously reported a
distinct functional behavour of peptide Ac2-26 compared to
AnxA1 in human neutrophils [16]; this was explained with the
ability of this peptide to bind many receptors of the FPR family
[14]. However, more relevant here since the HEK cells were
negative for FPR1, is the possibility that a part, possibly small, of
the effects of peptide Ac2-26 might be due to actions independent
from activation of any member of the FPR family [10].
Important from a pharmacological (and drug development)
perspective, we have shown here that microarray studies can be
used for more than merely identifying specific genes which are
altered Gene expression signature-based approaches can be very
instrumental for formulating hypotheses about novel mechanisms
of actions or new potential activities of known drugs. We report a
similar signature, partly expected, between AnxA1 and glucocor-
ticoids and the novel association between AnxA1 and HDACIs;
the latter, again, could act as a springboard for a comprehensive
assessment of the novel biological properties of all these
compounds
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